281 related articles for article (PubMed ID: 22588880)
1. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
Ni J; Liu Q; Xie S; Carlson C; Von T; Vogel K; Riddle S; Benes C; Eck M; Roberts T; Gray N; Zhao J
Cancer Discov; 2012 May; 2(5):425-33. PubMed ID: 22588880
[TBL] [Abstract][Full Text] [Related]
2. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
[TBL] [Abstract][Full Text] [Related]
3. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
4. CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.
Zhang J; Gao X; Schmit F; Adelmant G; Eck MJ; Marto JA; Zhao JJ; Roberts TM
Cell Rep; 2017 Jul; 20(3):549-557. PubMed ID: 28723560
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
6. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
7. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
8. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.
Cizmecioglu O; Ni J; Xie S; Zhao JJ; Roberts TM
Elife; 2016 Oct; 5():. PubMed ID: 27700986
[TBL] [Abstract][Full Text] [Related]
9. Molecular Profiling Establishes Genetic Features Predictive of the Efficacy of the p110β Inhibitor KIN-193.
Sethi I; Cai Z; Roberts TM; Yuan GC
Cancer Res; 2019 Sep; 79(17):4524-4531. PubMed ID: 31292159
[TBL] [Abstract][Full Text] [Related]
10. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
11. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
He C; Duan S; Dong L; Wang Y; Hu Q; Liu C; Forrest ML; Holzbeierlein JM; Han S; Li B
Prostate; 2017 Aug; 77(11):1187-1198. PubMed ID: 28631436
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Stamatkin C; Ratermann KL; Overley CW; Black EP
Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
[TBL] [Abstract][Full Text] [Related]
15. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
16. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas.
Xie S; Ni J; McFaline-Figueroa JR; Wang Y; Bronson RT; Ligon KL; Wen PY; Roberts TM; Zhao JJ
Cell Rep; 2020 Sep; 32(13):108196. PubMed ID: 32997991
[TBL] [Abstract][Full Text] [Related]
17. Beta-testing of PI3-kinase inhibitors: is beta better?
Shepherd PR; Denny WA
Cancer Discov; 2012 May; 2(5):393-4. PubMed ID: 22588874
[TBL] [Abstract][Full Text] [Related]
18. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
Jamieson S; Flanagan JU; Kolekar S; Buchanan C; Kendall JD; Lee WJ; Rewcastle GW; Denny WA; Singh R; Dickson J; Baguley BC; Shepherd PR
Biochem J; 2011 Aug; 438(1):53-62. PubMed ID: 21668414
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
20. Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases.
Jude JA; Tirumurugaan KG; Kang BN; Panettieri RA; Walseth TF; Kannan MS
Am J Respir Cell Mol Biol; 2012 Oct; 47(4):427-35. PubMed ID: 22556157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]